The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo

Cancer Chemotherapy and Pharmacology

Volumn 66, Issue 5, 2010, Pages 869-880

  Ackler, Scott ^a,c   Mitten, Michael J ^a   Foster, Kelly ^a   Oleksijew, Anatol ^a   Refici, Marion ^a   Tahir, Stephen K ^a   Xiao, Yu ^a   Tse, Christin ^a   Frost, David J ^a   Fesik, Stephen W ^b   Rosenberg, Saul H ^a   Elmore, Steven W ^a   Shoemaker, Alexander R ^a  

^a ABBOTT LABORATORIES   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Building AP3/105 ^*  (United States)

Author keywords

ABT 263; Apoptosis; Bcl 2; Lymphoma; Myeloma

Indexed keywords

4 [4 [2 (4 CHLOROPHENYL) 5,5 DIMETHYL 1 CYCLOHEXEN 1 YLMETHYL] 1 PIPERAZINYL] N [4 [3 MORPHOLINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 (TRIFLUOROMETHYLSULFONYL)BENZENESULFONYL]BENZAMIDE; BORTEZOMIB; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; PREDNISONE; PROTEIN BCL 2; PROTEIN NOXA; PUMA PROTEIN; RITUXIMAB; VINCRISTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LYMPHOMA; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; DRUG POTENTIATION; HEMATOLOGIC MALIGNANCY; IN VITRO STUDY; IN VIVO STUDY; LARGE CELL LYMPHOMA; LYMPHOMA CELL; MANTLE CELL LYMPHOMA; MOUSE; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR XENOGRAFT; UPREGULATION;

ANILINE COMPOUNDS; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS REGULATORY PROTEINS; CELL LINE, TUMOR; DRUG SYNERGISM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHOMA, B-CELL; MICE; MICE, SCID; MULTIPLE MYELOMA; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; SULFONAMIDES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77956225330     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-009-1232-1     Document Type: Article

References (44)

1. SEER Surveillance Epidemiology and End Results [homepage on the internet]. Bethesda: National Cancer Institute; c1973-2007 [updated 18 Dec 2007; cited 2 Jan 2008]. Cancer Stats Fact Sheet, Non-Hodgkin Lymphoma [top of page]. Available from: http://seer.cancer.gov/statfacts/html/nhl.html
2. RS Cvetkovic CM Perry 2006 Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia Drugs 66 791 820 10.2165/00003495-200666060-00005
3. RZ Orlowski DJ Kuhn 2008 Proteasome inhibitors in cancer therapy: lessons from the first decade Clin Cancer Res 14 1649 1657 10.1158/1078-0432.CCR-07- 2218
4. KN Utecht J Kolesar 2008 Bortezomib: a novel chemotherapeutic agent for hematologic malignancies Am J Health Syst Pharm 65 1221 1231 10.2146/ajhp070272
5. MC Wei 2004 Bcl-2-related genes in lymphoid neoplasia Int J Hematol 80 205 209 10.1532/IJH97.04110
6. JC Reed 1997 Bcl-2 family proteins: regulators of apoptosis and chemoresistance in hematologic malignancies Semin Hematol 34 9 19
7. Y Tsujimoto LR Finger J Yunis PC Nowell CM Croce 1984 Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation Science 226 1097 1099 10.1126/science.6093263
8. B Agarwal KN Naresh 2002 Bcl-2 family of proteins in indolent B-cell non-Hodgkin's lymphoma: study of 116 cases Am J Hematol 70 278 282 10.1002/ajh.10139
9. N Harada H Hata M Yoshida, et al. 1998 Expression of Bcl-2 family of proteins in fresh myeloma cells Leukemia 12 1817 1820 10.1038/sj.leu.2401168
10. AA Alizadeh MB Eisen RE Davis, et al. 2000 Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling Nature 403 503 511 10.1038/35000501
11. G Packham FK Stevenson 2005 Bodyguards and assassins: Bcl-2 family proteins and apoptosis control in chronic lymphocytic leukaemia Immunology 114 441 449 10.1111/j.1365-2567.2005.02117.x
12. Y Tu S Renner F Xu, et al. 1998 Bcl-X expression in multiple myeloma: possible indicator of chemoresistance Cancer Res 58 256 262
13. S Fukumi J Horiguchi-Yamada S Nakada M Nagai T Ohno H Yamada 2000 Differential responses of Bcl-2 family genes to etoposide in chronic myeloid leukemia K562 cells Mol Cell Biochem 206 43 50 10.1023/A:1007056727876
14. KV Floros H Thomadaki D Florou M Talieri A Scorilas 2006 Alterations in mRNA expression of apoptosis-related genes BCL2, BAX, FAS, caspase-3, and the novel member BCL2L12 after treatment of human leukemic cell line HL60 with the antineoplastic agent etoposide Ann N Y Acad Sci 1090 89 97 10.1196/annals.1378. 009
15. R Belhoussine H Morjani R Gillet V Palissot M Manfait 1999 Two distinct modes of oncoprotein expression during apoptosis resistance in vincristine and daunorubicin multidrug-resistant HL60 cells Adv Exp Med Biol 457 365 381
16. FT Liu SG Agrawal JG Gribben, et al. 2008 Bortezomib blocks Bax degradation in malignant B cells during treatment with TRAIL Blood 111 2797 2805 10.1182/blood-2007-08-110445
17. P Gomez-Bougie S Wuilleme-Toumi E Menoret, et al. 2007 Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma Cancer Res 67 5418 5424 10.1158/0008-5472.CAN-06-4322
18. JC Byrd S Kitada IW Flinn, et al. 2002 The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction Blood 99 1038 1043 10.1182/blood.V99.3.1038
19. C Tse AR Shoemaker J Adickes, et al. 2008 ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor Cancer Res 68 3421 3428 10.1158/0008-5472. CAN-07-5836
20. S Ackler Y Xiao MJ Mitten, et al. 2008 ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo Mol Cancer Ther 7 3265 3274 10.1158/1535-7163.MCT-08-0268
21. R Lock H Carol PJ Houghton, et al. 2008 Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program Pediatr Blood Cancer 50 1181 1189 10.1002/pbc.21433
22. V Del Gaizo Moore JR Brown M Certo TM Love CD Novina A Letai 2007 Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737 J Clin Invest 117 112 121 10.1172/JCI28281
23. L Paoluzzi M Gonen G Bhagat, et al. 2008 The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies Blood 112 2906 2916 10.1182/blood-2007-12-130781
24. MH Kang YH Kang B Szymanska, et al. 2007 Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo Blood 110 2057 2066 10.1182/blood-2007-03-080325
25. RM Mohammad S Wang A Aboukameel, et al. 2005 Preclinical studies of a nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-xL [(-)-gossypol] against diffuse large cell lymphoma Mol Cancer Ther 4 13 21
26. AJ Stel B Ten Cate S Jacobs, et al. 2007 Fas receptor clustering and involvement of the death receptor pathway in rituximab-mediated apoptosis with concomitant sensitization of lymphoma B cells to fas-induced apoptosis J Immunol 178 2287 2295
27. TC Chou P Talalay 1984 Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors Adv Enzyme Regul 22 27 55 10.1016/0065-2571(84)90007-4
28. AR Shoemaker A Oleksijew J Bauch, et al. 2006 A small-molecule inhibitor of Bcl-xL potentiates the activity of cytotoxic drugs in vitro and in vivo Cancer Res 66 8731 8739 10.1158/0008-5472.CAN-06-0367
29. NE Sladek 1988 Metabolism of oxazaphosphorines Pharmacol Ther 37 301 355 10.1016/0163-7258(88)90004-6
30. RM Mohammad A Al-Katib A Aboukameel DR Doerge F Sarkar O Kucuk 2003 Genistein sensitizes diffuse large cell lymphoma to CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy Mol Cancer Ther 2 1361 1368
31. FA Greco 1999 Oral etoposide in lymphoma Drugs 58 Suppl 3 35 41 10.2165/00003495-199958003-00006
32. SK Tahir X Yang MG Anderson, et al. 2007 Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737 Cancer Res 67 1176 1183 10.1158/0008-5472.CAN-06-2203
33. X Lin S Morgan-Lappe X Huang, et al. 2007 'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-xL inhibitor ABT-737 Oncogene 26 3972 3979 10.1038/sj.onc.1210166
34. M Konopleva R Contractor T Tsao, et al. 2006 Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia Cancer Cell 10 375 388 10.1016/j.ccr.2006.10.006
35. MF van Delft AH Wei KD Mason, et al. 2006 The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized Cancer Cell 10 389 399 10.1016/j.ccr.2006.08.027
36. AM Mandelin II RM Pope 2007 Myeloid cell leukemia-1 as a therapeutic target Expert Opin Ther Targets 11 363 373 10.1517/14728222.11.3.363
37. O Kutuk ED Arisan T Tezil MC Shoshan H Basaga 2009 Cisplatin overcomes Bcl-2-mediated resistance to apoptosis via preferential engagement of Bak: critical role of Noxa-mediated lipid peroxidation Carcinogenesis 30 1517 1527 10.1093/carcin/bgp165
38. SH Olejniczak FJ Hernandez-Ilizaliturri JL Clements MS Czuczman 2008 Acquired resistance to rituximab is associated with chemotherapy resistance resulting from decreased Bax and Bak expression Clin Cancer Res 14 1550 1560 10.1158/1078-0432.CCR-07-1255
39. AR Jazirehi MI Vega B Bonavida 2007 Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy Cancer Res 67 1270 1281 10.1158/0008-5472.CAN-06-2184
40. M Wobser H Voigt AO Eggert, et al. 2007 Bcl-2 expression in rituximab refractory cutaneous B-cell lymphoma Br J Cancer 96 1540 1543 10.1038/sj.bjc.6603762
41. RM Mohammad NR Wall JA Dutcher AM Al-Katib 2000 The addition of bryostatin 1 to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy improves response in a CHOP-resistant human diffuse large cell lymphoma xenograft model Clin Cancer Res 6 4950 4956
42. JC Reed S Kitada S Takayama T Miyashita 1994 Regulation of chemoresistance by the Bcl-2 oncoprotein in non-Hodgkin's lymphoma and lymphocytic leukemia cell lines Ann Oncol 5 Suppl 1 61 65
43. AJ Minn CM Rudin LH Boise CB Thompson 1995 Expression of Bcl-xL can confer a multidrug resistance phenotype Blood 86 1903 1910
44. Y Tu FH Xu J Liu, et al. 1996 Upregulated expression of BCL-2 in multiple myeloma cells induced by exposure to doxorubicin, etoposide, and hydrogen peroxide Blood 88 1805 1812